OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, highcholesterol and diabetes, has told DirtectorsTalk about the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.
The new patents reflect:-
· The success of its human studies designed to establish safety and efficacy on its capsular food supplement to reduce cholesterol
· The success of manufacturing studies designed to identify maximum production yields and volumes on its cholesterol reducing strain
· The identification of additional health benefits (hypertension reduction) shown by its cholesterol reducing strain
The Company believes that filing these patents adds a further layer of protection to its intellectual property portfolio, creates valuable assets, and increases the number of product opportunities.
Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce the filing of these patents which add a further level of protection and value to our cholesterol reducing product. We believe thesepatents will further enhance the value proposition and negotiating position with commercial partners and make a significant contribution to building a successful and sustainable business for shareholders.”
